Rochester Drug Cooperative, Inc. v. Biogen IDEC U.S. Corp.

130 F. Supp. 3d 764, 2015 WL 5474666
CourtDistrict Court, W.D. New York
DecidedSeptember 18, 2015
DocketNo. 6:15-CV-6388 EAW
StatusPublished
Cited by2 cases

This text of 130 F. Supp. 3d 764 (Rochester Drug Cooperative, Inc. v. Biogen IDEC U.S. Corp.) is published on Counsel Stack Legal Research, covering District Court, W.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Rochester Drug Cooperative, Inc. v. Biogen IDEC U.S. Corp., 130 F. Supp. 3d 764, 2015 WL 5474666 (W.D.N.Y. 2015).

Opinion

DECISION AND ORDER

ELIZABETH A; WOLFORD, District Judge.

INTRODUCTION

Plaintiff Rochester Drug Co-operative, Inc. (“Plaintiff’) has sued Defendant Biog-en Idee U.S. Corporation (“Defendant”)1 in connection with Defendant’s termination of a distribution contract with Plaintiff. Plaintiff alleges that Defendant’s termination decision was the product of unlawful arrangements reached between Defendant and three prominent national wholesalers to restrain trade in the sale of Avonex, a pharmaceutical drug manufactured by Defendant.

Plaintiffs Complaint against Defendant asserts five causes of action arising out of Defendant’s termination of its distribution contract'with Plaintiff: (1) violation of the Donnelly Act, N.Y. Gen. Bus. Law § 340; (2) injunctive relief under N.Y. CPLR 6301; (3) anticipatory breach of contract; (4) breach of the covenant of good faith and fair dealing; and (5) declaratory relief under N.Y. CPLR 3001. (Dkt. 1).

Defendant has moved.to dismiss the entire Complaint under Rule 12(b)(6) of the Federal Rules of Civil Procedure. (Dkt. 6). Plaintiff has moved for a preliminary injunction, restraining Defendant from taking any steps in furtherance of the termination decision. (Dkt. 9, 15). The Court held oral argument on September 15, 2015, and reserved decision.

The, Court is sensitive to the potential adverse impacts that Defendant’s termination decision may have on Defendant’s former regional wholesalers including Plaintiff, the local and independent pharmacies they service, and the pharmacies’ patients, particularly those living in rural areas. The indisputable trend in the pharmaceutical industry, as reflected in Defendant’s decision and similar decisions made by countless other pharmaceutical manufacturers, ’ is to distribute drugs through mammoth-sized wholesalers. As a result, the local community drug store, where prescriptions are filled while folks visit with their pharmacist and neighbors, appears to be fading from'our society, and their customers are increasingly being forced to obtain their pharmaceuticals through other means.

Nevertheless, the law permits corporations to make these types of distribution decisions without regard to societal impact, so long as they do not engage in an unlawful bilateral arrangement for anti-competitive purposes. Because Plaintiffs Complaint fails to plausibility allege that Defendant’s termination decision was the product of an unlawM reciprocal arrangement, "Defendant’s motion to dismiss (Dkt. 6) is granted and Plaintiffs Complaint (Dkt. 1) is dismissed in its entirety. Plaintiffs motion for' preliminary injunction (Dkt. 9) is denied.

[767]*767 BACKGROUND

I. The Parties

Plaintiff is a wholesale drug cooperative that buys and distributes a complete line of pharmaceuticals and home health supplies to community retail pharmacies, long-term care pharmacies, and home health care stores. (Dkt. 1, CompU 5). Plaintiffs customers are located primarily in New York, New Jersey, Pennsylvania, and Ohio, in both metropolitan and rural areas of those states. {Id. ¶ 6).

Defendant is a biotechnology corporation that develops, markets, and sells pharmaceutical products, including the drug Avonex. {Id. ¶ 7).

II. The Drug Avonex

Avonex treats “patients with relapsing forms of multiple sclerosis (‘MS’) to delay the progression of physical disability and reduce ‘flare ups’ of MS symptoms.” {Id. ¶ 10). Avonex is the only interferon beta on the market that is administered through intramuscular injection, as opposed to a subcutaneous injection. {Id. ¶ 41). Avonex needs to be administered only once a week. {Id.).

Avonex is sold in three formulations. The Avonex Pre-Filled Syringe is a conventional syringe. {Id. ¶ 10). The Avonex Powder Form is a lyophilized vial of powder that is manually mixed before injection. {Id.). The Avonex Pen is a prefilled needle that can be administered with a single click and “was designed to improve a patient’s ability to self-administer ’Avonex.” {Id. ¶ 13). According to Plaintiff, “[f]or many patients, Avonex is administered by licensed pharmacists in pharmacies.” {Id. ¶ 15).

III. The Big Three

Three wholesalers generate 85 to 90 percent of all revenues from drug distribution in the United States. {Id. ¶34). Those three wholesalers are Cardinal Health, McKesson Corporation, and AmerisourceBergen Corporation (commonly known as, and collectively referred to herein as, the “Big Three”). {Id.). They are the largest drug wholesalers in the nation. {Id.). The great majority of all pharmacies in the United States, including all of the large retail pharmacy chains, receive 'pharmaceuticals from the Big Three. {Id. ¶ 22).

The Big Three supply only to pharmácies that purchase a minimum volume amount of pharmaceuticals. {Id. ¶25). Many of the smaller pharmacy chains and independent pharmacies serviced by regional wholesalers like Plaintiff lack-.the volume requirements to purchase pharmaceuticals .from the Big Three. {Id. ¶¶ 24-25). ,

IY. The Wholesaler Distribution Agreement

On or about January 1, 2009; Plaintiff and Defendant entered into a Wholesaler Distribution Agreement (the “Distribution Agreement”), which was supplemented by Defendant’s letter dated March 14, 2012, whereby Plaintiff was appointed as an authorized wholesaler of Defendant’s Avonex products. {Id. ¶¶ 17-21). Plaintiff has performed under the Distribution Agreement for over six years. {Id. ¶ 19).

V. Termination of the Distribution Agreement

By letter dated March 23, 2015, Defendant informed Plaintiff that it was terminating the Distribution Agreement, effective June 30, -2015 (the “Termination Letter”). ■ {Id. ¶29). The' Termination Letter stated that> as of July 1, 2015, Avonex would be available for purchase only from the Big Three. {Id. ¶33). The Termination Letter also stated that Plaintiff could continue to sell Avonex out of its existing inventory for a period not to exceed 90 days from the date of termination. {Id. ¶ 54; Dkt. 6-4 at 2).

[768]*768VI. Allegations of Unlawful Arrangeititent

Plaintiffs allegations of unlawful arrangement • are located in paragraphs 52 through 56 of the Complaint. In paragraphs 52 and 53, Plaintiff. alleges that Defendant’s Termination Letter demonstrates that-Defendant has entered into an agreement or arrangement with the Big Three to exclude all other wholesalers, including Plaintiff,.from the relevant market, which is alleged to be “Avonex in all strengths and forms” in the United States. (Dkt. 1, Compl. ¶¶ 41, 52-53). In paragraph 54, Plaintiff alleges that-Defendant’s 90-day limit on the time by which Plaintiff must stop selling Avonex was instituted to protect the Big Three’s sales and profits. (Id ¶ 54)..

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
130 F. Supp. 3d 764, 2015 WL 5474666, Counsel Stack Legal Research, https://law.counselstack.com/opinion/rochester-drug-cooperative-inc-v-biogen-idec-us-corp-nywd-2015.